Keywords
Eligibility Determination ×
Ovarian Neoplasms ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

19 Search results.

Eligibility Ovarian Carcinoma NCT02244502

- 6/6/19 - 1 form, 2 itemgroups, 31 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety, Feasibility and Effect of TTFields Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02244502

Eligibility Ovarian Carcinoma NCT02025985

- 6/5/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase II Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies & Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02025985

Eligibility Epithelial Ovarian Carcinoma NCT02344095

- 3/28/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02344095

Eligibility Ovarian Cancer NCT01180504

- 9/12/18 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01180504 Sponsor: University Hospital Heidelberg Collaborator: Deutsche Krebshilfe e.V., Bonn (Germany) Information provided by: University Hospital Heidelberg Principal Investigator: Andreas Schneeweiss, MD Department of Gyneacology and Obstetrics, Unversity of Heidelberg Principal Investigator: Juergen Debus, MD, PhD Department of Radiation Oncology, University of Heidelberg

Eligibility Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers and Squamous Cell Carcinoma of the Head and Neck NCT01059643

- 9/3/18 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck; ODM derived from: https://clinicaltrials.gov/show/NCT01059643 Sponsor: Eli Lilly and Company Information provided by (Responsible Party): Eli Lilly and Company

Eligibility Ovarian Neoplasms NCT00841191

- 8/15/18 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00841191

Eligibility Ovarian Carcinoma NCT00853307

- 8/14/18 - 1 form, 2 itemgroups, 28 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
MLN8237 for Treatment of Patients With Ovarian, Fallopian Tube, or Peritoneal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00853307

Eligibility Ovarian Carcinoma NCT00721890

- 8/14/18 - 1 form, 2 itemgroups, 8 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Green Tea Intake for the Maintenance of Complete Remission in Women With Advanced Ovarian Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00721890

Eligibility Ovarian Cancer NCT00721162

- 8/14/18 - 1 form, 2 itemgroups, 34 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Ramucirumab in Ovarian Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00721162

Oral GW786034 treatment for ovarian cancer NCT00281632 - Screening Eligibility Criteria

- 4/14/18 - 1 form, 3 itemgroups, 31 items, 1 language
Itemgroups: Header, Inclusion Criteria, Exclusion Criteria
Study ID: 104450 Clinical Study ID: VEG104450 Study Title: This study is a non-randomized, open-label, multi-center Phase II study of GW786034 to evaluate the administration of oral GW786034 in subjects with ovarian cancer. Clinicaltrials.gov Identifier: NCT00281632 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib Trade Name: Votrient Study Indication: Neoplasms, Ovarian CRF Pages: 722-853

Eligibility Cancer NCT00756847

- 11/10/17 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00756847

Eligibility Ovarian Carcinoma NCT00474669

- 8/20/17 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase I Study of Intraperitoneal Hyperthermic Docetaxel; ODM derived from: https://clinicaltrials.gov/show/NCT00474669